Edition:
United States

Takara Bio Inc (4974.T)

4974.T on Tokyo Stock Exchange

1,506JPY
25 May 2017
Change (% chg)

¥-13 (-0.86%)
Prev Close
¥1,519
Open
¥1,522
Day's High
¥1,528
Day's Low
¥1,504
Volume
368,300
Avg. Vol
368,879
52-wk High
¥1,847
52-wk Low
¥1,140

4974.T

Chart for 4974.T

About

TAKARA BIO INC. is a biotechnological company. The Company has three business segments. The Genetic Engineering Research segment is involved in the research and development of biotechnology; the manufacture of research reagents; the sale, maintenance and repair of physics and chemistry equipment, such as reaction temperature... (more)

Overall

Beta: 1.71
Market Cap(Mil.): ¥182,911.30
Shares Outstanding(Mil.): 120.42
Dividend: --
Yield (%): 0.26

Financials

  4974.T Industry Sector
P/E (TTM): 135.29 141.29 17.43
EPS (TTM): 11.23 -- --
ROI: 2.22 2.17 -5.41
ROE: 2.26 0.10 -4.69

BRIEF-Takara Holdings' subsidiary Takara Bio says merger between US-based units

* Says the company's wholly owned US-based sub-subsidiary Takara Bio USA Inc plans to merge with co's other two wholly owned US-based sub-subsidiaries Rubicon Genomics Inc and WaferGen Bio-systems Inc, with effective date on March 31 (for Rubicon) and May 31 (for WaferGen)respectively

Mar 27 2017

BRIEF-Takara Holdings unit fully acquires WaferGen Bio-systems for $35.9 mln

* Says its subsidiary Takara Bio Inc's unit, Takara Bio USA Holdings Inc., fully acquired WaferGen Bio-systems, Inc at $35.9 million

Mar 01 2017

BRIEF-Takara Bio to start phase I/II clinical trials of gene therapy for sarcoma treatment

* Says the co to start phase I/II clinical trials of gene therapy for treatment of sarcoma

Jan 24 2017

BRIEF-Takara Bio's unit completes acquisition of Rubicon Genomics

* Says its wholly owned subsidiary Takara Bio USA Holdings Inc completes acquisition of Rubicon Genomics, Inc on Jan. 17 (US local time)

Jan 17 2017

More From Around the Web

Earnings vs. Estimates